Home LiteratureArticle Details
PMID: 19300869 Published · ppublish English Editorial

Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

The journal of nutrition, health & aging ·Vol. 13 ·No. 4 ·2009-04-00 ·Pages 332

Weiner MW

Abstract

暂无摘要

MeSH Terms
Alzheimer Disease/diagnosis Biomarkers/analysis Diagnostic Imaging Disease Progression Humans
Chemicals
Biomarkers
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Weiner M W
References (17)
17 references, click to expand
  1. How can we recognize "disease modification" effects?
    J Nutr Health Aging. 2009 Apr;13(4):341-3 PMID: 19300873
  2. Biomarkers for Alzheimer's disease trials--biomarkers for what? A discussion paper.
    J Nutr Health Aging. 2009 Apr;13(4):334-6 PMID: 19300870
  3. Interpreting biomarker data in therapeutic trials.
    J Nutr Health Aging. 2009 Apr;13(4):337-8 PMID: 19300871
  4. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers.
    J Nutr Health Aging. 2009 Apr;13(4):373-5 PMID: 19300885
  5. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.
    J Nutr Health Aging. 2009 Apr;13(4):370-2 PMID: 19300884
  6. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.
    J Nutr Health Aging. 2009 Apr;13(4):367-9 PMID: 19300883
  7. Structural imaging markers for therapeutic trials in Alzheimer's disease.
    J Nutr Health Aging. 2009 Apr;13(4):350-2 PMID: 19300877
  8. What we have learned from the Myriad trials.
    J Nutr Health Aging. 2009 Apr;13(4):362-4 PMID: 19300881
  9. Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment.
    J Nutr Health Aging. 2009 Apr;13(4):344-5 PMID: 19300874
  10. What we have learned from the Xaliproden Sanofi-aventis trials.
    J Nutr Health Aging. 2009 Apr;13(4):365-6 PMID: 19300882
  11. Interest of the new criteria for drug trials in AD.
    J Nutr Health Aging. 2009 Apr;13(4):356-7 PMID: 19300879
  12. Use of CSF biomarkers in Alzheimer's disease clinical trials.
    J Nutr Health Aging. 2009 Apr;13(4):358-61 PMID: 19300880
  13. Neuro-imaging: structural and functional imaging.
    J Nutr Health Aging. 2009 Apr;13(4):348-9 PMID: 19300876
  14. Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data.
    J Nutr Health Aging. 2009 Apr;13(4):353-5 PMID: 19300878
  15. Molecular imaging markers in clinical trials in Alzheimer s disease.
    J Nutr Health Aging. 2009 Apr;13(4):346-7 PMID: 19300875
  16. The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).
    J Nutr Health Aging. 2009 Apr;13(4):376-87 PMID: 19300886
  17. Biomarkers in clinical trials of Alzheimer disease (AD): what is expected from regulatory agencies?
    J Nutr Health Aging. 2009 Apr;13(4):339-40 PMID: 19300872
Article Info
Journal
The journal of nutrition, health & aging
Abbr.
J Nutr Health Aging
ISSN
1279-7707
DOI
10.1007/s12603-009-0032-y
Published
2009-04-00
Pages
332
Language
English
Region
France
NLM ID
100893366
Subset
IM
External Links
PubMed source DOI: 10.1007/s12603-009-0032-y View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2